CSOP Hang Seng Biotech ETF (03174.HK) Rises 4.84% Intraday after Ten Departments Issue the Pharmaceutical Industry 15th Five-Year Plan, Targeting 20%+ Annual Growth for Innovative Drugs

NewTimeSpace News: As of 15:04 on September 21, CSOP Hang Seng Biotech ETF (03174.HK) rose 4.84% to a latest price of HK$3.940, with an opening price of HK$3.768, a high of HK$3.952, a low of HK$3.768, and an intraday amplitude of 4.90%. The ETF traded 1.4429 million shares with a turnover of HK$5.6628 million, an average price of HK$3.925, and a premium rate of -0.16%. Its current net asset value per unit is HK$3.764, and its assets under management stand at HK$962.3 million.

(Note on scope: the net asset value per unit, assets under management and premium rate are as of September 18, 2026.)

On the news front, the Ministry of Industry and Information Technology, together with the National Development and Reform Commission, the National Medical Products Administration and seven other departments, issued the 15th Five-Year Plan for the Development of the Pharmaceutical Industry on September 18. The plan sets targets for 2030: the innovative drug industry is to grow at an average annual rate of above 20%, more than five products are to achieve global annual sales of over US$1 billion, first-in-class (FIC) drugs are to account for more than 25% of the global total, and more than 200 innovative medical devices are to be approved for listing. It also lays out 25 key tasks across eight areas, including innovation-driven development, precision diagnosis and treatment, and win-win openness, and explicitly sets out frontier tracks such as ADCs, nucleic acid drugs and CGT.

CSOP Hang Seng Biotech ETF (03174.HK) closely tracks the Hang Seng Biotech Index. The index reflects the overall performance of the 30 largest biotech companies that are listed in Hong Kong and tradable under the Southbound Stock Connect, including pre-revenue stocks listed through Chapter 18A of the Listing Rules of the Hong Kong Exchange; its constituents cover the "Biotechnology", "Pharmaceuticals", "Medicine Distribution", "Pharma & Biotech Contract Services" and "Medical Devices & Supplies" industry sub-categories under the Hang Seng Industry Classification System, and it is freefloat-adjusted market-capitalisation weighted with a 10% cap on individual stocks.

Zheshang Securities believes that AI-driven drug discovery has moved from an "algorithm narrative" to a "clinical delivery" stage, while the rate-limiting step in drug development iteration lies in wet-lab work, so the efficiency gains from AI will generate stronger demand for molecular validation; combined with the surge in demand for new molecular entities such as peptides and ADCs, the innovative drug industry chain forms a second line of certain growth for the sector.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.